A new industry report says that growth of the bio/pharmaceutical contract manufacturing sector is likely to be suppressed near-term, despite an increase in the number of product approvals, due to shrinking product volumes and high levels of capital investment by bio/pharmaceutical companies. According to PharmSource Information Services Inc., although contract manufacturing of bio/pharmaceutical finished dose forms grew at twice the rate of the overall industry during the 2012-2014 period, co...